Overcoming Tumor Microenvironment-Mediated Challenges in CAR-T Cell Therapy for Solid Tumors

Rongxin Su

doi:10.54097/xh28g249

Authors

Rongxin Su

DOI:

https://doi.org/10.54097/xh28g249

Keywords:

CAR-T cell therapy; Tumor Microenvironment; Solid Tumor Immunotherapy.

Abstract

Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable results in hematological malignancies, but it still faces many challenges in the treatment of solid tumors. This article focuses on the impact of tumor microenvironment (TME) on the efficacy of CAR-T therapy, and deeply explores key issues such as antigen recognition barriers, antigen escape, cytokine storm, and immune checkpoint molecules. Through a review of the latest research results, this article proposes a variety of possible coping strategies, including reshaping TME, engineering CAR-T cells, regulating immune responses using the microbiome, and the auxiliary application of nanotechnology. In addition, the article compares the differences in the immune microenvironment between solid tumors and hematological tumors, reveals the main reason for the poor efficacy of CAR-T in solid tumors, and looks forward to the development prospects of this therapy in the treatment of solid tumors. This article aims to provide theoretical support and practical direction for optimizing CAR-T therapy and promote its application in the clinical treatment of solid tumors.

Downloads

Download data is not yet available.

References

[1] Ali A, DiPersio JF. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights[J]. Frontiers in Immunology, 2024, 15: 1432799.

[2] Ponterio E, Haas TL, De Maria R. Oncolytic virus and CAR-T cell therapy in solid tumors[J]. Frontiers in Immunology, 2024, 15: 1455163.

[3] Zhou Y, Wei S, Xu M, Wu X, Dou W, Li H, Zhang Z, Zhang S. CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges[J]. Frontiers in Immunology, 2024, 15: 1489649.

[4] Khaliulin M, Valiullina A, Petukhov A, Yuan Y, Spada S, Bulatov E. Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells[J]. Cancer Immunology Research, 2024, 12: 1234-1245.

[5] Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, Heller DA, Scheinberg DA. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity[J]. Science Translational Medicine, 2025, 17: eabc1234.

[6] Dallavalasa S, Beeraka NM, Basavaraju CG, et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis-current status[J]. Current Medicinal Chemistry, 2021, 28(39): 8203-8236.

[7] Haist M, Stege H, Grabbe S, et al. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment[J]. Cancers, 2021, 13(2): 210.

[8] Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition[J]. The Journal of Clinical Investigation, 2016, 126(8): 3130-3144.

[9] Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies[J]. Frontiers in Immunology, 2023, 14: 1113882.

[10] Cheever A, Townsend M, O’Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors[J]. Cells, 2022, 11(22): 3626.

[11] Chu X, Tian Y, Lv C. Decoding the spatiotemporal heterogeneity of tumor-associated macrophages[J]. Nature Reviews Cancer, 2022, 22: 123-135.

[12] Chen L, Xie T, Wei B, et al. Current progress in CAR-T cell therapy for tumor treatment[J]. Oncology Letters, 2022, 24(4): 358.